Cargando…

On the Definition of Sarcopenia in the Presence of Aging and Obesity—Initial Results from UK Biobank

BACKGROUND: Current consensus is to combine a functional measure with muscle quantity to assess/confirm sarcopenia. However, the proper body size adjustment for muscle quantity is debated and sarcopenia in obesity is not well described. Further, functional measures are not muscle-specific or sensiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Linge, Jennifer, Heymsfield, Steven B, Dahlqvist Leinhard, Olof
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302181/
https://www.ncbi.nlm.nih.gov/pubmed/31642894
http://dx.doi.org/10.1093/gerona/glz229
_version_ 1783547799240966144
author Linge, Jennifer
Heymsfield, Steven B
Dahlqvist Leinhard, Olof
author_facet Linge, Jennifer
Heymsfield, Steven B
Dahlqvist Leinhard, Olof
author_sort Linge, Jennifer
collection PubMed
description BACKGROUND: Current consensus is to combine a functional measure with muscle quantity to assess/confirm sarcopenia. However, the proper body size adjustment for muscle quantity is debated and sarcopenia in obesity is not well described. Further, functional measures are not muscle-specific or sensitive to etiology, and can be confounded by, for example, fitness/pain. For effective detection/treatment/follow-up, muscle-specific biomarkers linked to function are needed. METHODS: Nine thousand six hundred and fifteen participants were included and current sarcopenia thresholds (EWGSOP2: DXA, hand grip strength) applied to investigate prevalence. Fat-tissue free muscle volume (FFMV) and muscle fat infiltration (MFI) were quantified through magnetic resonance imaging (MRI) and sex-and-body mass index (BMI)-matched virtual control groups (VCGs) were used to extract each participant’s FFMV/height(2) z-score (FFMV(VCG)). The value of combining FFMV(VCG) and MFI was investigated through hospital nights, hand grip strength, stair climbing, walking pace, and falls. RESULTS: Current thresholds showed decreased sarcopenia prevalence with increased BMI (underweight 8.5%/normal weight 4.3%/overweight 1.1%/obesity 0.1%). Contrary, the prevalence of low function increased with increasing BMI. Previously proposed body size adjustments (division by height(2)/weight/BMI) introduced body size correlations of larger/similar magnitude than before. VCG adjustment achieved normalization and strengthened associations with hospitalization/function. Hospital nights, low hand grip strength, slow walking pace, and no stair climbing were positively associated with MFI (p < .05) and negatively associated with FFMV(VCG) (p < .01). Only MFI was associated with falls (p < .01). FFMV(VCG) and MFI combined resulted in highest diagnostic performance detecting low function. CONCLUSIONS: VCG-adjusted FFMV enables proper sarcopenia assessment across BMI classes and strengthened the link to function. MFI and FFMV combined provides a more complete, muscle-specific description linked to function enabling objective sarcopenia detection.
format Online
Article
Text
id pubmed-7302181
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-73021812020-06-23 On the Definition of Sarcopenia in the Presence of Aging and Obesity—Initial Results from UK Biobank Linge, Jennifer Heymsfield, Steven B Dahlqvist Leinhard, Olof J Gerontol A Biol Sci Med Sci THE JOURNAL OF GERONTOLOGY: Medical Sciences BACKGROUND: Current consensus is to combine a functional measure with muscle quantity to assess/confirm sarcopenia. However, the proper body size adjustment for muscle quantity is debated and sarcopenia in obesity is not well described. Further, functional measures are not muscle-specific or sensitive to etiology, and can be confounded by, for example, fitness/pain. For effective detection/treatment/follow-up, muscle-specific biomarkers linked to function are needed. METHODS: Nine thousand six hundred and fifteen participants were included and current sarcopenia thresholds (EWGSOP2: DXA, hand grip strength) applied to investigate prevalence. Fat-tissue free muscle volume (FFMV) and muscle fat infiltration (MFI) were quantified through magnetic resonance imaging (MRI) and sex-and-body mass index (BMI)-matched virtual control groups (VCGs) were used to extract each participant’s FFMV/height(2) z-score (FFMV(VCG)). The value of combining FFMV(VCG) and MFI was investigated through hospital nights, hand grip strength, stair climbing, walking pace, and falls. RESULTS: Current thresholds showed decreased sarcopenia prevalence with increased BMI (underweight 8.5%/normal weight 4.3%/overweight 1.1%/obesity 0.1%). Contrary, the prevalence of low function increased with increasing BMI. Previously proposed body size adjustments (division by height(2)/weight/BMI) introduced body size correlations of larger/similar magnitude than before. VCG adjustment achieved normalization and strengthened associations with hospitalization/function. Hospital nights, low hand grip strength, slow walking pace, and no stair climbing were positively associated with MFI (p < .05) and negatively associated with FFMV(VCG) (p < .01). Only MFI was associated with falls (p < .01). FFMV(VCG) and MFI combined resulted in highest diagnostic performance detecting low function. CONCLUSIONS: VCG-adjusted FFMV enables proper sarcopenia assessment across BMI classes and strengthened the link to function. MFI and FFMV combined provides a more complete, muscle-specific description linked to function enabling objective sarcopenia detection. Oxford University Press 2020-06 2019-10-23 /pmc/articles/PMC7302181/ /pubmed/31642894 http://dx.doi.org/10.1093/gerona/glz229 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of The Gerontological Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle THE JOURNAL OF GERONTOLOGY: Medical Sciences
Linge, Jennifer
Heymsfield, Steven B
Dahlqvist Leinhard, Olof
On the Definition of Sarcopenia in the Presence of Aging and Obesity—Initial Results from UK Biobank
title On the Definition of Sarcopenia in the Presence of Aging and Obesity—Initial Results from UK Biobank
title_full On the Definition of Sarcopenia in the Presence of Aging and Obesity—Initial Results from UK Biobank
title_fullStr On the Definition of Sarcopenia in the Presence of Aging and Obesity—Initial Results from UK Biobank
title_full_unstemmed On the Definition of Sarcopenia in the Presence of Aging and Obesity—Initial Results from UK Biobank
title_short On the Definition of Sarcopenia in the Presence of Aging and Obesity—Initial Results from UK Biobank
title_sort on the definition of sarcopenia in the presence of aging and obesity—initial results from uk biobank
topic THE JOURNAL OF GERONTOLOGY: Medical Sciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302181/
https://www.ncbi.nlm.nih.gov/pubmed/31642894
http://dx.doi.org/10.1093/gerona/glz229
work_keys_str_mv AT lingejennifer onthedefinitionofsarcopeniainthepresenceofagingandobesityinitialresultsfromukbiobank
AT heymsfieldstevenb onthedefinitionofsarcopeniainthepresenceofagingandobesityinitialresultsfromukbiobank
AT dahlqvistleinhardolof onthedefinitionofsarcopeniainthepresenceofagingandobesityinitialresultsfromukbiobank